Status: Recruiting
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
Participants needed: 1,920
Trial details
Phase: Phase 3Age: 2+Biological sex: AllType: InterventionalSponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Updated: Sep 21, 2023Locations: 1
Eligibility criteria
Healthy subjects who meet the observation age of this clinical trial (2 years ol... [+3]
Previous vaccination with marketed or experimental pneumococcal vaccines; [+11]